Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Lymphoma

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 306 articles:
HTML format
Text format



Single Articles


    August 2019
  1. MELLERT K, Martin M, Lennerz JK, Ludeke M, et al
    The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Aug 12. doi: 10.1111/bjh.16147.
    PubMed     Text format     Abstract available


  2. MESGUICH C, Roch A, Hindie E, Milpied N, et al
    Prognostic utility of pre-transplantation [(18) F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage che
    Br J Haematol. 2019 Aug 6. doi: 10.1111/bjh.16144.
    PubMed     Text format     Abstract available


  3. PULSONI A, Della Starza I, Cappelli LV, Tosti ME, et al
    Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
    Br J Haematol. 2019 Aug 5. doi: 10.1111/bjh.16125.
    PubMed     Text format     Abstract available


  4. VANNATA B, Conconi A, Winkler J, Cascione L, et al
    Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome.
    Br J Haematol. 2019 Aug 5. doi: 10.1111/bjh.16106.
    PubMed     Text format     Abstract available


    July 2019
  5. MAGNANO L, Lopez-Guillermo A
    Minimal residual disease - ready for prime time in follicular lymphoma?
    Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16119.
    PubMed     Text format    


  6. FERRETTI A, Baldacci E, Miulli E, Canichella M, et al
    Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16114.
    PubMed     Text format    


  7. KONDO E, Shimizu-Koresawa R, Chihara D, Mizuta S, et al
    Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplant
    Br J Haematol. 2019 Jul 29. doi: 10.1111/bjh.16115.
    PubMed     Text format    


  8. DEMAGNY J, Guiheneuf E, Joris M, Garcon L, et al
    Hodgkin lymphoma infiltration with associated haemophagocytosis in bone marrow films.
    Br J Haematol. 2019 Jul 29. doi: 10.1111/bjh.16108.
    PubMed     Text format    


  9. WILSON MR, Bagguley T, Smith A, Roman E, et al
    Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study.
    Br J Haematol. 2019 Jul 25. doi: 10.1111/bjh.16109.
    PubMed     Text format    


  10. GUIDEZ S, Lacotte-Thierry L, Tomowiak C, Princet I, et al
    Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Jul 15. doi: 10.1111/bjh.16056.
    PubMed     Text format    


  11. DOMINGUEZ-PINILLA N, Martinez-Zamorano E, Campos-Martin Y, Algara Plana P, et al
    Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia.
    Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089.
    PubMed     Text format    


  12. MATSUE K, Abe Y, Narita K, Kobayashi H, et al
    Diagnosis of intravascular large B-cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years.
    Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16081.
    PubMed     Text format     Abstract available


  13. PRUSILA REI, Sorigue M, Jauhiainen J, Mercadal S, et al
    Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.
    Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16090.
    PubMed     Text format     Abstract available


  14. YORDANOVA K, Stilgenbauer S, Bohle RM, Lesan V, et al
    Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement.
    Br J Haematol. 2019 Jul 1. doi: 10.1111/bjh.16082.
    PubMed     Text format    


    June 2019
  15. LEE S, Fujita K, Negoro E, Morishita T, et al
    The impact of diagnostic wait time on the survival of patients with diffuse large B-cell lymphoma: effect modification by the International Prognostic Index.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16078.
    PubMed     Text format     Abstract available


  16. SAKAMOTO K, Shiba N, Deguchi T, Kiyokawa N, et al
    Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16080.
    PubMed     Text format     Abstract available


  17. CARRARO E, Mussolin L, Onofrillo D, Massano D, et al
    The revised International Paediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS): a test of applicability.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16079.
    PubMed     Text format    


  18. IKEDA C, Maruyama D, Oka H, Fujino T, et al
    Bone marrow involvement by monomorphic epitheliotropic intestinal T-cell lymphoma.
    Br J Haematol. 2019 Jun 25. doi: 10.1111/bjh.16073.
    PubMed     Text format    


  19. WIGHT JC, Yue M, Keane C, Johnston A, et al
    Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
    Br J Haematol. 2019 Jun 24. doi: 10.1111/bjh.16064.
    PubMed     Text format     Abstract available


  20. BLOMBERY P, Birkinshaw RW, Nguyen T, Gong JN, et al
    Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.
    Br J Haematol. 2019 Jun 24. doi: 10.1111/bjh.16069.
    PubMed     Text format    


  21. DJEBBARI F, Browning JA, Stanton L, Booth S, et al
    Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Jun 20. doi: 10.1111/bjh.16071.
    PubMed     Text format    


  22. ROY SF, Ghazawi FM, Powell J, Kokta V, et al
    EBV-associated hydroa vacciniforme-like T-cell lymphoma.
    Br J Haematol. 2019 Jun 19. doi: 10.1111/bjh.16065.
    PubMed     Text format    


  23. ONG DM, Ashby M, Grigg A, Gard G, et al
    Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.
    Br J Haematol. 2019 Jun 17. doi: 10.1111/bjh.16049.
    PubMed     Text format     Abstract available


  24. KATO H, Kato K, Kim SW, Fukuda T, et al
    Clinical outcomes of hepatitis B or C virus infections in patients with malignant lymphoma receiving autologous stem cell transplantation: on behalf of the Adult Lymphoma Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHC
    Br J Haematol. 2019 Jun 17. doi: 10.1111/bjh.16050.
    PubMed     Text format    


  25. KELLY KM, Cole PD, Pei Q, Bush R, et al
    Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.
    Br J Haematol. 2019 Jun 10. doi: 10.1111/bjh.16014.
    PubMed     Text format     Abstract available


  26. SPURGEON SE, Sharma K, Claxton DF, Ehmann C, et al
    Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.
    Br J Haematol. 2019 Jun 9. doi: 10.1111/bjh.16008.
    PubMed     Text format     Abstract available


  27. CASULO C
    How I manage patients with follicular lymphoma.
    Br J Haematol. 2019 Jun 7. doi: 10.1111/bjh.16011.
    PubMed     Text format     Abstract available


  28. CHEN Z, Liu W, Zhao S
    Systemic EBV-positive T-cell lymphoma of childhood mimicking anaplastic large cell lymphoma.
    Br J Haematol. 2019;185:1016.
    PubMed     Text format    


    May 2019
  29. WANG Y, Maurer MJ, Larson MC, Allmer C, et al
    Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.
    Br J Haematol. 2019 May 28. doi: 10.1111/bjh.15997.
    PubMed     Text format     Abstract available


  30. FARRUGIA D, Grech M, Camilleri D
    Mantle cell lymphoma with lymphocyte aggregates in peripheral blood.
    Br J Haematol. 2019 May 24. doi: 10.1111/bjh.15976.
    PubMed     Text format    


  31. KHOGEER H, Rahman H, Jain N, Angelova EA, et al
    Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15960.
    PubMed     Text format     Abstract available


  32. CAIRO MS
    Rituximab in the treatment of childhood mature B-cell lymphoma: "Where do we go from here".
    Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15940.
    PubMed     Text format    


  33. TOYODA K, Tsukasaki K, Machida R, Kadota T, et al
    Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
    Br J Haematol. 2019 May 16. doi: 10.1111/bjh.15950.
    PubMed     Text format     Abstract available


  34. NIJDAM A, Dekker N, Aleman BMP, van 't Veer MB, et al
    Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma.
    Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15936.
    PubMed     Text format    


  35. MASCHAN A, Myakova N, Aleinikova O, Abugova Y, et al
    Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M.
    Br J Haematol. 2019 May 9. doi: 10.1111/bjh.15944.
    PubMed     Text format     Abstract available


  36. GEER M, Roberts E, Shango M, Till BG, et al
    Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.
    Br J Haematol. 2019 May 1. doi: 10.1111/bjh.15923.
    PubMed     Text format     Abstract available


    April 2019
  37. BURKART M, Schieber M, Basu S, Shah P, et al
    Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma.
    Br J Haematol. 2019 Apr 2. doi: 10.1111/bjh.15889.
    PubMed     Text format     Abstract available


    March 2019
  38. GHOSH N, Sanikommu S, Robinson M, Trivedi J, et al
    Curative potential of chemoimmunotherapy in diffuse large B cell lymphoma with hepatic and/or renal dysfunction.
    Br J Haematol. 2019 Mar 28. doi: 10.1111/bjh.15897.
    PubMed     Text format    


  39. BECNEL MR, Nastoupil LJ, Samaniego F, Davis RE, et al
    Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
    Br J Haematol. 2019 Mar 28. doi: 10.1111/bjh.15843.
    PubMed     Text format     Abstract available


  40. LIU F, Kang L, Wang Y
    Cutaneous flushing associated with Hodgkin lymphoma.
    Br J Haematol. 2019 Mar 24. doi: 10.1111/bjh.15873.
    PubMed     Text format    


  41. HAPGOOD G, Ben-Neriah S, Mottok A, Lee DG, et al
    Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.
    Br J Haematol. 2019 Mar 14. doi: 10.1111/bjh.15860.
    PubMed     Text format    


  42. PAVLOVSKY A, Fernandez I, Kurgansky N, Prates V, et al
    PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
    Br J Haematol. 2019 Mar 12. doi: 10.1111/bjh.15838.
    PubMed     Text format     Abstract available


  43. CHEN L, Li S, Wang M, Li Y, et al
    Expansion deficiency of CAR-T cells in patients with lymphoma and resolution by T cell purification.
    Br J Haematol. 2019 Mar 4. doi: 10.1111/bjh.15822.
    PubMed     Text format    


    February 2019
  44. KHASHAB T, Hagemeister F, Romaguera JE, Fanale MA, et al
    Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 28. doi: 10.1111/bjh.15814.
    PubMed     Text format     Abstract available


  45. BURKHARDT B, Hermiston ML
    Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
    Br J Haematol. 2019 Feb 27. doi: 10.1111/bjh.15793.
    PubMed     Text format     Abstract available


  46. MAGNANO L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, et al
    Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.
    Br J Haematol. 2019 Feb 22. doi: 10.1111/bjh.15805.
    PubMed     Text format     Abstract available


  47. RUSCONI C, Anastasia A, Chiarenza A, Marcheselli L, et al
    Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
    Br J Haematol. 2019 Feb 21. doi: 10.1111/bjh.15816.
    PubMed     Text format     Abstract available


  48. IMATAKI O, Uemura M, Kadowaki N
    Lethal cardiac damage resulting from eosinophilia caused by anaplastic large cell lymphoma.
    Br J Haematol. 2019 Feb 21. doi: 10.1111/bjh.15809.
    PubMed     Text format    


  49. MUNDT F, Merrien M, Nygren L, Sutton LA, et al
    Expression of GNAZ, encoding the Galphaz protein, predicts survival in mantle cell lymphoma.
    Br J Haematol. 2019 Feb 20. doi: 10.1111/bjh.15810.
    PubMed     Text format     Abstract available


  50. MIYAMURA T, Moritake H, Nakayama H, Tanaka S, et al
    Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15799.
    PubMed     Text format     Abstract available


  51. GALARDY PJ, Bedekovics T, Macintyre E, Miles RR, et al
    Lymphoma diagnostics: getting more from less.
    Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15788.
    PubMed     Text format     Abstract available


  52. O'REILLY MA, Govender D, Kirkwood AA, Vora A, et al
    The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
    Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15798.
    PubMed     Text format    


  53. ROMANO A, Parrinello NL, Chiarenza A, Motta G, et al
    Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.
    Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15801.
    PubMed     Text format     Abstract available


  54. CHIU H, Trisal P, Bjorklund C, Carrancio S, et al
    Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Br J Haematol. 2019 Feb 14. doi: 10.1111/bjh.15797.
    PubMed     Text format     Abstract available


  55. LEES C, Keane C, Gandhi MK, Gunawardana J, et al
    Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.
    Br J Haematol. 2019 Feb 10. doi: 10.1111/bjh.15778.
    PubMed     Text format     Abstract available


  56. CHANTADA G, Lam CG, Howard SC
    Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment.
    Br J Haematol. 2019 Feb 10. doi: 10.1111/bjh.15785.
    PubMed     Text format     Abstract available


  57. CAIRO MS, Beishuizen A
    Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15764.
    PubMed     Text format     Abstract available


  58. ZANELLI M, Zizzo M, De Marco L, Bisagni A, et al
    Fibrin-associated diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15786.
    PubMed     Text format    


  59. METZGER ML, Mauz-Korholz C
    Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15789.
    PubMed     Text format     Abstract available


  60. ROSENBAUM CA, Jung SH, Pitcher B, Bartlett NL, et al
    Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
    Br J Haematol. 2019 Feb 5. doi: 10.1111/bjh.15768.
    PubMed     Text format     Abstract available


  61. VU K, Mannis G, Hwang J, Geng H, et al
    Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
    Br J Haematol. 2019 Feb 3. doi: 10.1111/bjh.15787.
    PubMed     Text format    


  62. EHRHARDT MJ, Hochberg J, Bjornard KL, Brinkman TM, et al
    Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 3. doi: 10.1111/bjh.15775.
    PubMed     Text format     Abstract available


    January 2019
  63. DANIEL V, Delamain MT, Murbach BA, de Souza CA, et al
    Role for DNA base-excision repair gene variants in the prognosis of Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 31. doi: 10.1111/bjh.15779.
    PubMed     Text format    


  64. BARTH MJ, Minard-Colin V
    Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 30. doi: 10.1111/bjh.15783.
    PubMed     Text format     Abstract available


  65. PACZKOWSKA J, Soloch N, Bodnar M, Kiwerska K, et al
    Expression of ELF1, a lymphoid ETS domain-containing transcription factor, is recurrently lost in classical Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 25. doi: 10.1111/bjh.15757.
    PubMed     Text format     Abstract available


  66. CANNATA-ORTIZ J, Nicolas C, Garcia-Noblejas A, Requena MJ, et al
    Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI >/= 2 follicular lymphoma. Final results of the LNH-PRO-05 study.
    Br J Haematol. 2019 Jan 17. doi: 10.1111/bjh.15760.
    PubMed     Text format    


  67. BATALLER A, Combalia A, Garcia-Herrera A, Estrach T, et al
    Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15744.
    PubMed     Text format    


  68. CHU Y, Gardenswartz A, Termuhlen AM, Cairo MS, et al
    Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15753.
    PubMed     Text format     Abstract available


  69. CWYNARSKI K, Marzolini MAV, Barrington SF, Follows G, et al
    The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2019 Jan 4. doi: 10.1111/bjh.15731.
    PubMed     Text format    


  70. EVENS AM
    Important new developments in Hodgkin Lymphoma.
    Br J Haematol. 2019;184:6.
    PubMed     Text format    


    December 2018
  71. NAKAYAMA S, Taniguchi T, Tanaka H, Espinoza JL, et al
    Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome.
    Br J Haematol. 2018 Dec 28. doi: 10.1111/bjh.15733.
    PubMed     Text format    


  72. BOLL B, Plutschow A, Burkle C, Atta J, et al
    Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
    Br J Haematol. 2018 Dec 28. doi: 10.1111/bjh.15741.
    PubMed     Text format     Abstract available


  73. HILL BT, Nastoupil L, Winter AM, Becnel MR, et al
    Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Br J Haematol. 2018 Dec 21. doi: 10.1111/bjh.15720.
    PubMed     Text format     Abstract available


  74. RULE S, Cook G, Russell NH, Hunter A, et al
    Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
    Br J Haematol. 2018 Dec 17. doi: 10.1111/bjh.15723.
    PubMed     Text format     Abstract available


  75. REDONDO AM, Valcarcel D, Gonzalez-Rodriguez AP, Suarez-Lledo M, et al
    Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
    Br J Haematol. 2018 Dec 12. doi: 10.1111/bjh.15713.
    PubMed     Text format     Abstract available


  76. LIN RJ, Ho C, Hilden PD, Barker JN, et al
    Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
    Br J Haematol. 2018 Dec 11. doi: 10.1111/bjh.15721.
    PubMed     Text format     Abstract available


  77. VON KEUDELL G, Younes A
    Novel therapeutic agents for relapsed classical Hodgkin lymphoma.
    Br J Haematol. 2018 Dec 11. doi: 10.1111/bjh.15695.
    PubMed     Text format     Abstract available


  78. UMAKANTHAN JM, Iqbal J, Batlevi CL, Bouska A, et al
    Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
    Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15702.
    PubMed     Text format     Abstract available


  79. FRIEDRICHS B, Nickelsen M, Ziepert M, Altmann B, et al
    Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
    Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15710.
    PubMed     Text format     Abstract available


  80. RIVAS-DELGADO A, Magnano L, Moreno-Velazquez M, Garcia O, et al
    Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.
    Br J Haematol. 2018 Dec 4. doi: 10.1111/bjh.15708.
    PubMed     Text format     Abstract available


  81. HOHLOCH K, Windemuth-Kieselbach C, Kolz J, Zinzani PL, et al
    Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry.
    Br J Haematol. 2018 Dec 4. doi: 10.1111/bjh.15712.
    PubMed     Text format     Abstract available


  82. GHOLIHA AR, Hollander P, Hedstrom G, Sundstrom C, et al
    High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.
    Br J Haematol. 2018 Dec 2. doi: 10.1111/bjh.15703.
    PubMed     Text format     Abstract available


    November 2018
  83. LUO J, Wang SS, Lu Y, Sullivan-Halley J, et al
    Pregnancy-related factors and risk of B-cell non-Hodgkin lymphoma among women in Los Angeles.
    Br J Haematol. 2018 Nov 29. doi: 10.1111/bjh.15699.
    PubMed     Text format    


  84. SPINNER MA, Varma G, Advani RH
    Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 28. doi: 10.1111/bjh.15616.
    PubMed     Text format     Abstract available


  85. TANIGUCHI T, Nakayama S, Morita Y, Rai S, et al
    Antidiuretic hormone- and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion.
    Br J Haematol. 2018 Nov 28. doi: 10.1111/bjh.15689.
    PubMed     Text format    


  86. VISSER L
    Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?
    Br J Haematol. 2018 Nov 28. doi: 10.1111/bjh.15704.
    PubMed     Text format    


  87. MCCULLOCH R, Smith A, Crosbie N, Patmore R, et al
    Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma.
    Br J Haematol. 2018 Nov 26. doi: 10.1111/bjh.15696.
    PubMed     Text format    


  88. FOX CP, Phillips EH, Smith J, Linton K, et al
    Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.
    Br J Haematol. 2018 Nov 23. doi: 10.1111/bjh.15661.
    PubMed     Text format    


  89. BRIERLEY CK, Jones FM, Hanlon K, Peniket AJ, et al
    Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
    Br J Haematol. 2018 Nov 22. doi: 10.1111/bjh.15685.
    PubMed     Text format     Abstract available


  90. CROMBIE JL, LaCasce AS
    Current considerations in AYA Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 20. doi: 10.1111/bjh.15640.
    PubMed     Text format     Abstract available


  91. STENGEL A, Kern W, Meggendorfer M, Haferlach T, et al
    Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Br J Haematol. 2018 Nov 20. doi: 10.1111/bjh.15653.
    PubMed     Text format    


  92. PAINSCHAB MS, Kasonkanji E, Zuze T, Kaimila B, et al
    Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort.
    Br J Haematol. 2018 Nov 18. doi: 10.1111/bjh.15625.
    PubMed     Text format     Abstract available


  93. ADAMS HJA, Kwee TC
    Interim FDG-PET does not predict outcome in advanced-stage Hodgkin lymphoma patients treated with BEACOPP.
    Br J Haematol. 2018 Nov 14. doi: 10.1111/bjh.15602.
    PubMed     Text format    


  94. GALATI D, Zanotta S, Corazzelli G, Bruzzese D, et al
    Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 13. doi: 10.1111/bjh.15676.
    PubMed     Text format     Abstract available


  95. CIRILLO M, Reinke S, Klapper W, Borchmann S, et al
    The translational science of hodgkin lymphoma.
    Br J Haematol. 2018 Nov 12. doi: 10.1111/bjh.15658.
    PubMed     Text format     Abstract available


  96. MITSUI T, Yokohama A, Koiso H, Saito A, et al
    Prognostic impact of trisomy 21 in follicular lymphoma.
    Br J Haematol. 2018 Nov 12. doi: 10.1111/bjh.15664.
    PubMed     Text format     Abstract available


  97. LONGLEY J, Johnson PWM
    Current treatment paradigms for advanced stage Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15622.
    PubMed     Text format     Abstract available


  98. HIEMCKE-JIWA LS, Leguit RJ, Snijders TJ, Bromberg JEC, et al
    MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15674.
    PubMed     Text format    


  99. PAINTER D, Barrans S, Lacy S, Smith A, et al
    Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15619.
    PubMed     Text format    


  100. HIEMCKE-JIWA LS, Leguit RJ, Jiwa NM, Huibers MMH, et al
    CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15670.
    PubMed     Text format    


  101. IANNITTO E, Bellei M, Amorim S, Ferreri AJM, et al
    Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15641.
    PubMed     Text format     Abstract available


  102. VALCHEV G, Alaikov T, Shivarov V
    Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15662.
    PubMed     Text format    


  103. BOLL B, Gorgen H
    The treatment of older Hodgkin lymphoma patients.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15652.
    PubMed     Text format     Abstract available


  104. VISCO C, Tisi MC, Evangelista A, Di Rocco A, et al
    Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15643.
    PubMed     Text format    


  105. MAYBURY B, Kimpton G, Otton S
    A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15637.
    PubMed     Text format    


  106. BROCCOLI A, Zinzani PL
    The role of transplantation in Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15639.
    PubMed     Text format     Abstract available


  107. WANG HW, Balakrishna JP, Pittaluga S, Jaffe ES, et al
    Diagnosis of Hodgkin lymphoma in the modern era.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15614.
    PubMed     Text format     Abstract available


  108. BAECH J, Hansen SM, Lund PE, Soegaard P, et al
    Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15603.
    PubMed     Text format     Abstract available


  109. BUDDE LE, Wu D, Martin DB, Philip M, et al
    Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
    Br J Haematol. 2018;183:601-607.
    PubMed     Text format     Abstract available


    October 2018
  110. TALAULIKAR D, Biscoe A, Lim JH, Gibson J, et al
    Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenstrom Macroglobulinaemia reveals different patterns of clonal evolution.
    Br J Haematol. 2018 Oct 18. doi: 10.1111/bjh.15610.
    PubMed     Text format    


    September 2018
  111. BROCKELMANN PJ, McMullen S, Wilson JB, Mueller K, et al
    Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.
    Br J Haematol. 2018 Sep 21. doi: 10.1111/bjh.15566.
    PubMed     Text format     Abstract available


  112. CENCINI E, Sicuranza A, Fabbri A, Ferrigno I, et al
    Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
    Br J Haematol. 2018 Sep 11. doi: 10.1111/bjh.15582.
    PubMed     Text format     Abstract available


  113. FAULK KE, Sopfe JM, Campbell K, Liptzin DR, et al
    Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.
    Br J Haematol. 2018 Sep 10. doi: 10.1111/bjh.15586.
    PubMed     Text format     Abstract available


  114. JIANG C, Bi C, Jiang X, Tian T, et al
    The miR-17~92 cluster activates mTORC1 in mantle cell lymphoma by targeting multiple regulators in the STK11/AMPK/TSC/mTOR pathway.
    Br J Haematol. 2018 Sep 10. doi: 10.1111/bjh.15591.
    PubMed     Text format    


  115. BRANDEFORS L, Melin B, Lindh J, Lundqvist K, et al
    Prognostic factors and primary treatment for Waldenstrom macroglobulinemia - a Swedish Lymphoma Registry study.
    Br J Haematol. 2018 Sep 10. doi: 10.1111/bjh.15558.
    PubMed     Text format     Abstract available


  116. ANDORSKY DJ, Kolibaba KS, Assouline S, Forero-Torres A, et al
    An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    Br J Haematol. 2018 Sep 5. doi: 10.1111/bjh.15552.
    PubMed     Text format     Abstract available


  117. JAIN P, Kanagal-Shamanna R, Zhang S, Ahmed M, et al
    Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Br J Haematol. 2018 Sep 2. doi: 10.1111/bjh.15567.
    PubMed     Text format     Abstract available



  118. Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma Abstracts, 26-29 September 2018, De Doelen International Congress Centre, Rotterdam, Netherlands.
    Br J Haematol. 2018;182 Suppl 1:5-109.
    PubMed     Text format    


    August 2018
  119. WALEWSKI J, Hellmann A, Siritanaratkul N, Ozsan GH, et al
    Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
    Br J Haematol. 2018 Aug 30. doi: 10.1111/bjh.15539.
    PubMed     Text format     Abstract available


  120. SETO AG, Beatty X, Lynch JM, Hermreck M, et al
    Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma.
    Br J Haematol. 2018 Aug 20. doi: 10.1111/bjh.15547.
    PubMed     Text format     Abstract available


  121. HWANG AE, Marshall V, Conti DV, Nathwani BN, et al
    Epstein-Barr virus load is higher in long-term Hodgkin lymphoma survivors compared to their unaffected twins and unrelated controls.
    Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15522.
    PubMed     Text format    


  122. GYAN E, Sonet A, Brice P, Anglaret B, et al
    Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
    Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15513.
    PubMed     Text format     Abstract available


  123. FRAZER JK, Li KJ, Galardy PJ, Perkins SL, et al
    Excellent outcomes in children and adolescents with CNS(+) burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1.
    Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15520.
    PubMed     Text format    


  124. RAUERT-WUNDERLICH H, Mottok A, Scott DW, Rimsza LM, et al
    Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.
    Br J Haematol. 2018 Aug 10. doi: 10.1111/bjh.15519.
    PubMed     Text format     Abstract available


  125. MURBACH BA, Delamain MT, Daniel V, de Souza CA, et al
    Association between polymorphisms in angiogenesis-related genes and the prognosis of classical Hodgkin lymphoma.
    Br J Haematol. 2018 Aug 6. doi: 10.1111/bjh.15512.
    PubMed     Text format    


  126. SU C, Bai HX, Xiao R
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some of the apparent ethnic dispa
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15526.
    PubMed     Text format    


  127. LO BELLO G, Naresh KN
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some apparent ethnic disparities.
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15527.
    PubMed     Text format    


    July 2018
  128. BIGENWALD C, Fardet L, Coppo P, Meignin V, et al
    A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis.
    Br J Haematol. 2018 Jul 24. doi: 10.1111/bjh.15506.
    PubMed     Text format     Abstract available


  129. CAIRO M, Auperin A, Perkins SL, Pinkerton R, et al
    Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.
    Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15491.
    PubMed     Text format     Abstract available


  130. AVIVI I, Arcaini L, Ferretti VV, Boumendil A, et al
    High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
    Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15454.
    PubMed     Text format     Abstract available


  131. KHAN UT, Racu-Amoasii I, Arumainathan A, Meswani U, et al
    Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis.
    Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15489.
    PubMed     Text format    


  132. TRACHTENBERG E, Mashiach T, Ben Hayun R, Tadmor T, et al
    Cognitive impairment in hodgkin lymphoma survivors.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15448.
    PubMed     Text format     Abstract available


  133. NITTA H, Gotoh A, Tanaka M, Sekiguchi Y, et al
    Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15431.
    PubMed     Text format    


  134. AILAWADHI S, Dholaria BR, Khurana S, Sher T, et al
    Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15458.
    PubMed     Text format    


  135. EL-SHARKAWI D, Ng CH, Payne EM, Yong KL, et al
    Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15457.
    PubMed     Text format    


  136. MONTALBAN C, Diaz-Lopez A, Martin A, Baile M, et al
    Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15446.
    PubMed     Text format     Abstract available


  137. CHIHARA D, Oki Y, Fanale MA, Westin JR, et al
    Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15444.
    PubMed     Text format    


    June 2018
  138. AZOULAY D, Nasser R, Sharon R, Simanovich L, et al
    Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine-induced peripheral neuropathy in patients with lymphoma.
    Br J Haematol. 2018 Jun 25. doi: 10.1111/bjh.15428.
    PubMed     Text format    


  139. DERENZINI E, Agostinelli C, Rossi A, Rossi M, et al
    Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma.
    Br J Haematol. 2018 Jun 17. doi: 10.1111/bjh.15442.
    PubMed     Text format    


  140. MCKAY P, Leach M, Jackson B, Robinson S, et al
    A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma.
    Br J Haematol. 2018 Jun 8. doi: 10.1111/bjh.15281.
    PubMed     Text format    


  141. BLACKLAWS J, Seamone ME, Gupta RR
    Spectral domain optical coherence tomography interpretation.
    Br J Haematol. 2018;181:710.
    PubMed     Text format    


  142. FEND F, Coupland S
    Spectral domain optical coherence tomography interpretation - Response to Blacklaws et al.
    Br J Haematol. 2018;181:711.
    PubMed     Text format    


  143. FELDMAN AL, Flowers CR
    Ethnic disparity in primary cutaneous CD30(+) T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer database.
    Br J Haematol. 2018;181:721-722.
    PubMed     Text format    


    May 2018
  144. KOMMALAPATI A, Tella SH, Go RS, Nowakowski GS, et al
    T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes.
    Br J Haematol. 2018 May 30. doi: 10.1111/bjh.15391.
    PubMed     Text format    


  145. VAN WESTRHENEN A, Smidt LCA, Seute T, Nierkens S, et al
    Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review.
    Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15410.
    PubMed     Text format     Abstract available


  146. KURT H, Medeiros LJ, Khoury JD, Schlette EJ, et al
    Epstein-Barr virus-positive follicular lymphoma.
    Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15419.
    PubMed     Text format    


  147. FAMA A, Xiang J, Link BK, Allmer C, et al
    Human Pegivirus infection and lymphoma risk and prognosis: a North American study.
    Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15416.
    PubMed     Text format     Abstract available


  148. GISSELBRECHT C, Van Den Neste E
    How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
    Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15412.
    PubMed     Text format     Abstract available


  149. WITTE H, Biersack H, Kopelke S, Rades D, et al
    The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma.
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15198.
    PubMed     Text format    


  150. SHI J, Bodo J, Zhao X, Durkin L, et al
    SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target.
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15393.
    PubMed     Text format    


  151. MARALDO MV, Illidge TM
    How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15256.
    PubMed     Text format    


  152. JAIN P, Romaguera J, Srour SA, Lee HJ, et al
    Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15411.
    PubMed     Text format     Abstract available


  153. MCKAY P, Leach M, Jackson B, Robinson S, et al
    Guideline for the management of mantle cell lymphoma.
    Br J Haematol. 2018 May 16. doi: 10.1111/bjh.15283.
    PubMed     Text format    


  154. BRAM EDNERSSON S, Stenson M, Stern M, Enblad G, et al
    Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients.
    Br J Haematol. 2018 May 16. doi: 10.1111/bjh.15259.
    PubMed     Text format     Abstract available


  155. MANWANI R, Wrench D, Wechalekar A, Lachmann H, et al
    Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma.
    Br J Haematol. 2018 May 16. doi: 10.1111/bjh.15269.
    PubMed     Text format    


  156. VERA-LOZADA G, Barros MHM, Alves P, Segges P, et al
    EOMES/TBET and soluble CTLA4/full length CTLA4 expression ratios impact on the therapeutic response in patients with classical Hodgkin lymphoma.
    Br J Haematol. 2018 May 9. doi: 10.1111/bjh.15253.
    PubMed     Text format    


  157. ZHU KY, Song KW, Connors JM, Leitch H, et al
    Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Br J Haematol. 2018 May 9. doi: 10.1111/bjh.15262.
    PubMed     Text format     Abstract available


  158. ROMAGUERA JE, Lee HJ, Tarapore R, Prabhu V, et al
    Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
    Br J Haematol. 2018 May 8. doi: 10.1111/bjh.15271.
    PubMed     Text format    


  159. MCMASTER ML, Sun C, Landi MT, Savage SA, et al
    Germline mutations in Protection of Telomeres 1 in two families with Hodgkin lymphoma.
    Br J Haematol. 2018;181:372-377.
    PubMed     Text format     Abstract available


  160. OLSZEWSKI AJ, Ollila T, Reagan JL
    Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.
    Br J Haematol. 2018;181:495-504.
    PubMed     Text format     Abstract available


  161. LI Z, Lu L, Zhou Z, Xue W, et al
    Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma.
    Br J Haematol. 2018;181:406-410.
    PubMed     Text format    


  162. BOND J, Touzart A, Nadal N, Trinquand A, et al
    Early thymic precursor-like lymphomatous presentation of the ETV6-NCOA2 translocation.
    Br J Haematol. 2018;181:392-394.
    PubMed     Text format    


    April 2018
  163. PARSONS SK, Kelly MJ, Cohen JT, Castellino SM, et al
    Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.
    Br J Haematol. 2018 Apr 29. doi: 10.1111/bjh.15255.
    PubMed     Text format     Abstract available


  164. CHIN CK, Tsang E, Mediwake H, Khair W, et al
    Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15173.
    PubMed     Text format    


  165. KARIMI P, Birmann BM, Anderson LA, McShane CM, et al
    Risk factors for Burkitt lymphoma: a nested case-control study in the UK Clinical Practice Research Datalink.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15229.
    PubMed     Text format     Abstract available


  166. FRIDTHJOF KS, Kampmann P, Dunweber A, Gorlov JS, et al
    Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15249.
    PubMed     Text format     Abstract available


  167. MALIK B, Taylor GP
    Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15234.
    PubMed     Text format    


  168. FEDERICO M, Bellei M, Marcheselli L, Schwartz M, et al
    Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.
    Br J Haematol. 2018 Apr 19. doi: 10.1111/bjh.15258.
    PubMed     Text format     Abstract available


  169. DEAU B, Amorim S, Perrot A, Quittet P, et al
    Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15184.
    PubMed     Text format     Abstract available


  170. SPRIANO F, Chung EY, Panini N, Cascione L, et al
    Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15212.
    PubMed     Text format    


  171. LINK BK, Day BM, Zhou X, Zelenetz AD, et al
    Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15149.
    PubMed     Text format    


  172. CITRIN R, Getz KD, Li Y, Huang YS, et al
    The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15159.
    PubMed     Text format    


  173. SINGAVI AK, Shah NN
    Graft-versus-host disease-associated hepatic portal venous gas.
    Br J Haematol. 2018;181:9.
    PubMed     Text format    


  174. GALANINA N, Smith SM, Liao C, Petrich A, et al
    University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
    Br J Haematol. 2018;181:264-267.
    PubMed     Text format    


  175. GIFFORD G, Gabrielli S, Gill A, Greenwood M, et al
    Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.
    Br J Haematol. 2018;181:272-275.
    PubMed     Text format    


  176. MESGUICH C, Cazeau AL, Bouabdallah K, Hindie E, et al
    Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.
    Br J Haematol. 2018;181:124-125.
    PubMed     Text format    


  177. ADAMS HJA, Kwee TC
    Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?
    Br J Haematol. 2018;181:122-123.
    PubMed     Text format    


  178. RESTELLI V, Vagni M, Arribas AJ, Bertoni F, et al
    Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
    Br J Haematol. 2018;181:129-133.
    PubMed     Text format    


    March 2018
  179. NGUYEN KA, Su C, Bai HX, Zhang Z, et al
    Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the US National Cancer Database.
    Br J Haematol. 2018 Mar 30. doi: 10.1111/bjh.15145.
    PubMed     Text format     Abstract available


  180. SMITH A, Roman E, Appleton S, Howell D, et al
    Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
    Br J Haematol. 2018 Mar 13. doi: 10.1111/bjh.15170.
    PubMed     Text format     Abstract available


  181. MINSON A, Douglas G, Bilmon I, Grigg A, et al
    Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.
    Br J Haematol. 2018 Mar 13. doi: 10.1111/bjh.15186.
    PubMed     Text format    


  182. MELANI C, Wilson WH, Roschewski M
    What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R?
    Br J Haematol. 2018 Mar 13. doi: 10.1111/bjh.15185.
    PubMed     Text format    


  183. SHAH NN, Fenske TS, Hamadani M, Svoboda J, et al
    What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15183.
    PubMed     Text format    


  184. LEE HJ, Badillo M, Romaguera J, Wang M, et al
    A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15107.
    PubMed     Text format    


  185. VAN TIENEN C, Visser O, Lugtenburg P, Taylor G, et al
    Overrepresentation of patients from HTLV-1 endemic countries among T cell Non-Hodgkin lymphomas in the Netherlands: an indication of under-diagnosis of Adult T cell leukaemia/lymphoma.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15160.
    PubMed     Text format    


  186. CASTILLO JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, et al
    Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15156.
    PubMed     Text format    


  187. LAVOLE J, Le Goff M, Oudjit A, Sogni P, et al
    Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
    Br J Haematol. 2018;180:629.
    PubMed     Text format    


  188. KALAC M, Lue JK, Lichtenstein E, Turenne I, et al
    Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
    Br J Haematol. 2018;180:757-760.
    PubMed     Text format    


  189. NISHINO M, Ramaiya NH, Hatabu H, Hodi FS, et al
    PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.
    Br J Haematol. 2018;180:752-755.
    PubMed     Text format    


  190. DI NAPOLI A, Jain P, Duranti E, Margolskee E, et al
    Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.
    Br J Haematol. 2018;180:741-744.
    PubMed     Text format    


  191. STASILOJC G, Felberg A, Okroj M
    Parameters critical for the effector mechanism of anti-CD20 antibodies revisited.
    Br J Haematol. 2018;180:777-779.
    PubMed     Text format    


  192. MENTER T, Medani H, Olavarria E, Kanfer E, et al
    Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2018;180:904-908.
    PubMed     Text format    


  193. ALLEN PB, Pavone ME, Smith KN, Kazer RR, et al
    The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experience.
    Br J Haematol. 2018;180:901-904.
    PubMed     Text format    


    February 2018
  194. BELTRAN BE, Castro D, De La Cruz-Vargas JA, Cotrina E, et al
    The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma.
    Br J Haematol. 2018 Feb 26. doi: 10.1111/bjh.15141.
    PubMed     Text format    


  195. KARAM JD, Zerbib Y, Meyer ME, Delette C, et al
    Spontaneous tumour lysis syndrome in a primary adrenal lymphoma.
    Br J Haematol. 2018 Feb 26. doi: 10.1111/bjh.15143.
    PubMed     Text format    


  196. VACHHANI P, Neppalli VT, Cancino CJ, Bogner P, et al
    Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.
    Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15154.
    PubMed     Text format    


  197. BAZARBACHI A, Boumendil A, Finel H, Mohty M, et al
    Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
    Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15152.
    PubMed     Text format     Abstract available


  198. HUDSON KE, Rizzieri D, Thomas SM, LeBlanc TW, et al
    Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.
    Br J Haematol. 2018 Feb 21. doi: 10.1111/bjh.15138.
    PubMed     Text format    


  199. DEMARIA L, Henry J, Seror R, Frenzel L, et al
    Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjogren syndrome (pSS).
    Br J Haematol. 2018 Feb 9. doi: 10.1111/bjh.15120.
    PubMed     Text format    


  200. ISHIDA T, Jo T, Takemoto S, Suzushima H, et al
    Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15123.
    PubMed     Text format    


  201. BOUTAULT R, Le Glaunec J, Debord C, Robillard N, et al
    Diagnosis of a lymphoma associated with human herpes virus 8 aided by flow cytometric immunophenotyping.
    Br J Haematol. 2018 Feb 1. doi: 10.1111/bjh.14968.
    PubMed     Text format    


  202. FOX TA, Jager R, Ardeshna KM
    Cerebrospinal fluid leak after bone marrow biopsy.
    Br J Haematol. 2018;180:319.
    PubMed     Text format    


    January 2018
  203. JIANG H, Lwin T, Zhao X, Ren Y, et al
    Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
    Br J Haematol. 2018 Jan 30. doi: 10.1111/bjh.15079.
    PubMed     Text format    


  204. SMYTH L, Buckstein R, Pennell N, Weerasinghe R, et al
    Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-alpha induces prolonged clinical and molecular remissions in patients with follicular lymphoma.
    Br J Haematol. 2018 Jan 30. doi: 10.1111/bjh.15118.
    PubMed     Text format    


  205. RUTHERFORD SC, Leonard JP
    Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee.
    Br J Haematol. 2018 Jan 29. doi: 10.1111/bjh.15113.
    PubMed     Text format    


  206. HERSHKOVITZ-ROKAH O, Pulver D, Lenz G, Shpilberg O, et al
    Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
    Br J Haematol. 2018 Jan 23. doi: 10.1111/bjh.15108.
    PubMed     Text format     Abstract available


    December 2017
  207. REDDY JP, Hernandez M, Gunther JR, Dabaja BS, et al
    Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.
    Br J Haematol. 2017 Dec 21. doi: 10.1111/bjh.15054.
    PubMed     Text format     Abstract available


  208. ROVO A, Kulasekararaj A, Medinger M, Chevallier P, et al
    Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15074.
    PubMed     Text format    


  209. ADAMS HJA, Kwee TC
    Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15071.
    PubMed     Text format    


  210. MILGROM SA, Pinnix CC, Gunther JR, Fanale M, et al
    Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15072.
    PubMed     Text format    


  211. GHIONE P, Cavallo F, Visco C, Chen Z, et al
    A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15057.
    PubMed     Text format    


  212. SHAH NN, Szabo A, Huntington SF, Epperla N, et al
    R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15051.
    PubMed     Text format     Abstract available


  213. SOLAL-CELIGNY P, Leconte P, Bardet A, Hernandez J, et al
    A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
    Br J Haematol. 2017 Dec 12. doi: 10.1111/bjh.15023.
    PubMed     Text format     Abstract available


  214. SCHICK M, Habringer S, Nilsson JA, Keller U, et al
    Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
    Br J Haematol. 2017;179:724-738.
    PubMed     Text format     Abstract available


  215. RADESKI D, Montanari F, Alobeid B, O'Connor OA, et al
    Post-transplant lymphoproliferative disorder: a heterogeneous conundrum - response to Weisenburger DD & Gross TG.
    Br J Haematol. 2017;179:856-857.
    PubMed     Text format    


  216. WEISENBURGER DD, Gross TG
    Post-transplant lymphoproliferative disorder: a heterogeneous conundrum.
    Br J Haematol. 2017;179:854-856.
    PubMed     Text format    


    November 2017
  217. FLINN IW, Thompson DS, Boccia RV, Miletello G, et al
    Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15044.
    PubMed     Text format     Abstract available


  218. ARCAINI L, Lamy T, Walewski J, Belada D, et al
    Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15025.
    PubMed     Text format     Abstract available


  219. HOHLOCH K, Altmann B, Pfreundschuh M, Loeffler M, et al
    Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15029.
    PubMed     Text format     Abstract available


  220. ZAMO A, Pischimarov J, Horn H, Ott G, et al
    The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15041.
    PubMed     Text format     Abstract available


  221. FRAME IJ, Coberly J, Fuda FS, Chen M, et al
    Erythrophagocytosis by T-cell lymphoma cells in a patient with hereditary spherocytosis post-splenectomy.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15028.
    PubMed     Text format    


  222. KARAKAWA A, Taoka K, Kaburaki T, Tanaka R, et al
    Clinical features and outcomes of secondary intraocular lymphoma.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15005.
    PubMed     Text format    


  223. LIN RJ, Ma H, Guo R, Troxel AB, et al
    Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15027.
    PubMed     Text format     Abstract available


  224. PFREUNDSCHUH M, Murawski N, Zeynalova S, Ziepert M, et al
    Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
    Br J Haematol. 2017;179:410-420.
    PubMed     Text format     Abstract available


  225. MENTER T, Medani H, Ahmad R, Flora R, et al
    MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.
    Br J Haematol. 2017;179:681-684.
    PubMed     Text format    


    October 2017
  226. GIULINO-ROTH L, O'Donohue T, Chen Z, Bartlett NL, et al
    Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Br J Haematol. 2017 Oct 29. doi: 10.1111/bjh.14951.
    PubMed     Text format     Abstract available


  227. PRETTYJOHNS M, Hoskin P, McNamara C, Linch D, et al
    The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14990.
    PubMed     Text format     Abstract available


  228. QIU Y, Li Z, Pouzoulet F, Vishnu P, et al
    Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.15009.
    PubMed     Text format    


  229. CHASE ML, Armand P
    Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14996.
    PubMed     Text format     Abstract available


  230. MANSO R, Sanchez-Beato M, Gonzalez-Rincon J, Gomez S, et al
    Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14984.
    PubMed     Text format    


  231. GAUDIO E, Paduano F, Pinton S, D'Agostino S, et al
    TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.
    Br J Haematol. 2017 Oct 19. doi: 10.1111/bjh.14989.
    PubMed     Text format    


  232. CORNISH N, Maybury B, Otton S
    A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2017 Oct 19. doi: 10.1111/bjh.14959.
    PubMed     Text format    


  233. EDLINGER L, Berger-Becvar A, Menzl I, Hoermann G, et al
    Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.
    Br J Haematol. 2017;179:229-241.
    PubMed     Text format     Abstract available


    September 2017
  234. THANARAJASINGAM G, Maurer MJ, Farooq U, Johnston PB, et al
    Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.
    Br J Haematol. 2017 Sep 29. doi: 10.1111/bjh.14922.
    PubMed     Text format    


  235. ADAMS HJA, Kwee TC
    Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2017 Sep 14. doi: 10.1111/bjh.14906.
    PubMed     Text format    


  236. YAMANI F, Chen W
    Cytokeratin-positive primary effusion lymphoma: a diagnostic challenge.
    Br J Haematol. 2017 Sep 7. doi: 10.1111/bjh.14904.
    PubMed     Text format    


  237. PROCHAZKA KT, Posch F, Deutsch A, Beham-Schmid C, et al
    Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma.
    Br J Haematol. 2017 Sep 6. doi: 10.1111/bjh.14912.
    PubMed     Text format    


  238. OTT G
    Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
    Br J Haematol. 2017;178:871-887.
    PubMed     Text format     Abstract available


  239. GOCKERITZ E, Vondey V, Guastafierro A, Pizevska M, et al
    Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    Br J Haematol. 2017;178:949-953.
    PubMed     Text format     Abstract available


  240. MADDY L, Campbell PJ, Kipp D, Rose HL, et al
    Richter syndrome presenting as Sister Mary Joseph umbilical nodule.
    Br J Haematol. 2017;178:659.
    PubMed     Text format    


    August 2017
  241. EYRE TA, Phillips EH, Linton KM, Kassam S, et al
    Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
    Br J Haematol. 2017 Aug 31. doi: 10.1111/bjh.14898.
    PubMed     Text format     Abstract available


  242. MUSSOLIN L, Pillon M, Zimmermann M, Carraro E, et al
    Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma.
    Br J Haematol. 2017 Aug 31. doi: 10.1111/bjh.14864.
    PubMed     Text format    


  243. DANN EJ, Paltiel O
    Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14905.
    PubMed     Text format    


  244. RULE S, Dreyling M, Goy A, Hess G, et al
    Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14870.
    PubMed     Text format     Abstract available


  245. MILGROM SA, Pinnix CC, Chuang H, Oki Y, et al
    Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14902.
    PubMed     Text format     Abstract available


  246. COX MC, Di Napoli A, Fabbri A, Cencini E, et al
    The significance of serum immunoglobulin paraprotein in diffuse large B-cell lymphoma.
    Br J Haematol. 2017 Aug 17. doi: 10.1111/bjh.14873.
    PubMed     Text format    


  247. ALONSO-ALVAREZ S, Magnano L, Alcoceba M, Andrade-Campos M, et al
    Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Br J Haematol. 2017 Aug 7. doi: 10.1111/bjh.14831.
    PubMed     Text format     Abstract available


  248. KANATE AS, DiGilio A, Ahn KW, Al Malki M, et al
    Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14879.
    PubMed     Text format    


  249. JAIN P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, et al
    Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14857.
    PubMed     Text format    


  250. HAGNER PR, Chiu H, Ortiz M, Apollonio B, et al
    Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14866.
    PubMed     Text format     Abstract available


  251. FERRERI AJM, Cecchetti C, Kiesewetter B, Sassone M, et al
    Clarithromycin as a "repurposing drug" against MALT lymphoma.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14878.
    PubMed     Text format    


  252. ZWAAN CM, Kowalczyk J, Schmitt C, Bielorai B, et al
    Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14874.
    PubMed     Text format     Abstract available


  253. MAKAROVA O, Oschlies I, Muller S, Ruf S, et al
    Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14868.
    PubMed     Text format    


  254. DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
    Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
    PubMed     Text format     Abstract available


  255. SROUR SA, Li S, Popat UR, Qazilbash MH, et al
    A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Br J Haematol. 2017;178:561-570.
    PubMed     Text format     Abstract available


  256. EYRE TA, Schuh A
    An update for Richter syndrome - new directions and developments.
    Br J Haematol. 2017;178:508-520.
    PubMed     Text format     Abstract available


    July 2017
  257. SHIVAROV V, Ivanova M
    Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14861.
    PubMed     Text format    


  258. CASCIONE L, Rinaldi A, Chiappella A, Kwee I, et al
    Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14817.
    PubMed     Text format    


  259. DELLA PEPA R, Picardi M, Giordano C, Zacheo I, et al
    Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14856.
    PubMed     Text format    


  260. WESTMORELAND KD, El-Mallawany NK, Kazembe P, Stanley CC, et al
    Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment.
    Br J Haematol. 2017 Jul 17. doi: 10.1111/bjh.14716.
    PubMed     Text format    


  261. MANSO R, Martinez-Magunacelaya N, Chamizo C, Rojo F, et al
    Mutual regulation between BCL6 and a specific set of miRNAs controls TFH phenotype in peripheral T-cell lymphoma.
    Br J Haematol. 2017 Jul 12. doi: 10.1111/bjh.14824.
    PubMed     Text format    


  262. KABURAKI T, Taoka K, Matsuda J, Yamashita H, et al
    Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma.
    Br J Haematol. 2017 Jul 12. doi: 10.1111/bjh.14848.
    PubMed     Text format     Abstract available


  263. TOMITA N
    Histological assessment at follicular lymphoma progression.
    Br J Haematol. 2017 Jul 7. doi: 10.1111/bjh.14834.
    PubMed     Text format    


  264. DANG NH, Ogura M, Castaigne S, Fayad LE, et al
    Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14820.
    PubMed     Text format    


  265. RUTHERFORD SC, Li V, Ghione P, Chen Z, et al
    Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14839.
    PubMed     Text format     Abstract available


  266. MENTER T, Juskevicius D, Alikian M, Steiger J, et al
    Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
    Br J Haematol. 2017;178:48-56.
    PubMed     Text format     Abstract available


    June 2017
  267. FAROOQ U, Maurer MJ, Thompson CA, Thanarajasingam G, et al
    Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14813.
    PubMed     Text format     Abstract available


  268. BERNASCONI E, Gaudio E, Lejeune P, Tarantelli C, et al
    Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14803.
    PubMed     Text format     Abstract available


  269. MODVIG L, Vase M, d'Amore F
    Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14822.
    PubMed     Text format     Abstract available


  270. SZCZEPANOWSKI M, Lange J, Kohler CW, Masque-Soler N, et al
    Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14812.
    PubMed     Text format     Abstract available


  271. PRATT G, Yap C, Oldreive C, Slade D, et al
    A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14793.
    PubMed     Text format    


  272. STRUSSMANN T, Fritsch K, Baumgarten A, Fietz T, et al
    Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14802.
    PubMed     Text format     Abstract available


  273. LI L, Duan W, Zhang L, Li X, et al
    The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
    Br J Haematol. 2017 Jun 9. doi: 10.1111/bjh.14763.
    PubMed     Text format     Abstract available


  274. DANN EJ, Bairey O, Bar-Shalom R, Mashiach T, et al
    Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Br J Haematol. 2017 Jun 7. doi: 10.1111/bjh.14734.
    PubMed     Text format     Abstract available


    May 2017
  275. TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
    PubMed     Text format     Abstract available


  276. BECH RS, Nielsen KL, Larsen TS, Bentzen HH, et al
    Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.
    Br J Haematol. 2017 May 23. doi: 10.1111/bjh.14775.
    PubMed     Text format    


  277. FONSECA E SILVA D, Lopes MS, Pedrosa C, Regadas L, et al
    Burkitt lymphoma.
    Br J Haematol. 2017 May 16. doi: 10.1111/bjh.14758.
    PubMed     Text format    


  278. SHIMONO J, Miyoshi H, Kiyasu J, Sato K, et al
    Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma.
    Br J Haematol. 2017 May 11. doi: 10.1111/bjh.14736.
    PubMed     Text format     Abstract available


  279. LI Y, Wang L, Zhu HY, Liang JH, et al
    Prognostic significance of serum immunoglobulin paraprotein in patients with diffuse large B cell lymphoma.
    Br J Haematol. 2017 May 11. doi: 10.1111/bjh.14735.
    PubMed     Text format    


  280. CHASTY B, Patterson M, Murray LJ, Johnson R, et al
    Lack of effectiveness of routine clinic and blood test-based follow-up for diffuse large B cell lymphoma.
    Br J Haematol. 2017 May 9. doi: 10.1111/bjh.14745.
    PubMed     Text format    


  281. CERIANI L, Martelli M, Conconi A, Zinzani PL, et al
    Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.
    Br J Haematol. 2017 May 9. doi: 10.1111/bjh.14728.
    PubMed     Text format     Abstract available


  282. CEDERLEUF H, Bjerregard Pedersen M, Jerkeman M, Relander T, et al
    The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
    Br J Haematol. 2017 May 8. doi: 10.1111/bjh.14740.
    PubMed     Text format     Abstract available


  283. LEE S, Day NS, Miles RR, Perkins SL, et al
    Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.
    Br J Haematol. 2017 May 4. doi: 10.1111/bjh.14604.
    PubMed     Text format     Abstract available


  284. BOYLE T, Connors JM, Gascoyne RD, Berry BR, et al
    Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14702.
    PubMed     Text format     Abstract available


  285. EPPERLA N, Pham AQ, Burnette BL, Wiseman GA, et al
    Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14688.
    PubMed     Text format     Abstract available


    April 2017
  286. EPPERLA N, Hamadani M, Fenske TS, Costa LJ, et al
    Incidence and survival trends in mantle cell lymphoma.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14699.
    PubMed     Text format    


  287. BATLEVI CL, Crump M, Andreadis C, Rizzieri D, et al
    A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14698.
    PubMed     Text format     Abstract available


  288. HUSSAIN S, Hallam S, Beltran L, Haroon A, et al
    Intravascular large B-cell lymphoma presenting as a pituitary mass with bilateral adrenal enlargement and haemophagocytic lymphohistiocytosis.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14715.
    PubMed     Text format    


  289. HUDE I, Sasse S, Brockelmann PJ, von Tresckow B, et al
    Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14705.
    PubMed     Text format    


  290. CAVALLI M, De Novi LA, Della Starza I, Cappelli LV, et al
    Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14616.
    PubMed     Text format     Abstract available


  291. MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
    Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
    PubMed     Text format     Abstract available


  292. TOKUNAGA M, Yonekura K, Nakamura D, Haraguchi K, et al
    Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14634.
    PubMed     Text format    


  293. WANG Z, Cook JR
    PDCD1LG2 (PD-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma.
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14670.
    PubMed     Text format    


  294. SZYCHOT E, Shankar A, Haider A, Ramsay A, et al
    Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation?
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14607.
    PubMed     Text format    


  295. SROUR SA, Lee HJ, Nomie K, Ye H, et al
    Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
    Br J Haematol. 2017 Apr 2. doi: 10.1111/bjh.14669.
    PubMed     Text format    


  296. CHAN KL, Blombery P, Jones K, Lade S, et al
    Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.
    Br J Haematol. 2017;177:324-328.
    PubMed     Text format    


  297. ADAMS HJ, Kwee TC
    Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score?
    Br J Haematol. 2017;177:319-320.
    PubMed     Text format    


  298. BISHTON MJ, McMillan AK, Fox CP
    Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.
    Br J Haematol. 2017;177:320-321.
    PubMed     Text format    


    March 2017
  299. EYRE TA, Osborne WL, Gallop-Evans E, Ardeshna KM, et al
    Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14665.
    PubMed     Text format    


  300. NASTOUPIL LJ, McLaughlin P, Feng L, Neelapu SS, et al
    High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14541.
    PubMed     Text format     Abstract available


  301. CHEN RW, Li H, Bernstein SH, Kahwash S, et al
    RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
    Br J Haematol. 2017;176:759-769.
    PubMed     Text format     Abstract available


    February 2017
  302. MYLAM KJ, Michaelsen TY, Hutchings M, Jacobsen Pulczynski E, et al
    Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study.
    Br J Haematol. 2017;176:671-673.
    PubMed     Text format    


    January 2017
  303. RUBIO-GONZALEZ B, Zain J, Rosen ST, Querfeld C, et al
    Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.
    Br J Haematol. 2017;176:16-36.
    PubMed     Text format     Abstract available


    June 2016
  304. WILLIAMS ME, Hong F, Gascoyne RD, Wagner LI, et al
    Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Br J Haematol. 2016;173:867-75.
    PubMed     Text format     Abstract available


    April 2016
  305. BARTA SK, Joshi J, Mounier N, Xue X, et al
    Central nervous system involvement in AIDS-related lymphomas.
    Br J Haematol. 2016 Apr 7. doi: 10.1111/bjh.13998.
    PubMed     Text format     Abstract available


    August 2015
  306. SHARMA POUDYAL B, Gyawali B, Tuladhar S, Kapali K, et al
    Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal.
    Br J Haematol. 2015 Aug 25. doi: 10.1111/bjh.13645.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: